Johnson & Johnson lifts 2026 guidance, shares trade higher on NYSE
Published on 06/24/2026 at 10:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-24, 10:51.
Johnson & Johnson (US4781601046) raised its full-year 2026 outlook after a strong first quarter, with the shares trading on the New York Stock Exchange above 239 dollars as of the latest data. The updated guidance and upcoming second-quarter earnings in mid-July keep the health care group firmly on the S&P 500 radar, according to recent analyst and market commentary.International Business Times report on the guidance raise
What the guidance update shows
Per recent coverage, Johnson & Johnson now projects reported 2026 sales between 100.3 billion and 101.3 billion dollars, reflecting stronger-than-anticipated demand in its pharmaceuticals and medtech franchises.IBTimes breakdown of the new outlook Adjusted earnings per share are expected in a range of 11.45 to 11.65 dollars, implying mid- to high-single-digit growth versus prior years, underpinned by pipeline launches and label expansions.
Analyst expectations ahead of Q2
Analysts currently model second-quarter earnings per share around 2.83 dollars, with earnings projected to expand at roughly 8 percent annually over the coming years and revenue growth near 6 percent per year, based on recent consensus figures.IBTimes summary of earnings projections One AI-driven analyst tool assigns Johnson & Johnson a Hold rating with an AI Score of 6 out of 10, indicating a modest probability advantage of beating the S&P 500 over the next three months.Danelfin AI analysis on J&J
All news and data on the Johnson & Johnson shares
Further articles, quotes and background information on Johnson & Johnson are available in the dedicated topic section and via the company’s Investor Relations page.
The products behind the stock
Johnson & Johnson generates its revenue across three main segments: innovative pharmaceuticals, medical devices and consumer health products. Well-known brands include the Stelara immunology franchise, orthopaedic and surgical devices, and consumer staples such as Tylenol and Johnson’s baby care products, which together provide diversified cash flows across economic cycles.Johnson & Johnson company overview
Where the shares trade today
The Johnson & Johnson shares (US4781601046) last traded on the New York Stock Exchange at around 239.08 dollars as of 2026-06-23, 23:59 EDT, with a recent daily move of roughly 3.4 percent and a market capitalization near 575 billion dollars.Fidelity factsheet with latest J&J quote
Johnson & Johnson at a glance
- Company: Johnson & Johnson
- ISIN: US4781601046
- WKN: 853260
- Ticker: JNJ
- Trading venue: NYSE
- Price (as of 2026-06-23, 23:59 EDT): 239.08 USD
- Market cap: 575.5 billion USD (as of 2026-06-23)
- Sector / industry: Health Care, Pharmaceuticals & Medical Devices
- Index membership: S&P 500, Dow Jones Industrial Average
- Next earnings date: mid-July 2026 (company guidance)
Disclaimer: This article provides factual information and context on Johnson & Johnson shares and does not contain investment advice or a recommendation to buy or sell the stock.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
